Glassia is a prescription therapy used to treat alpha-1 antitrypsin deficiency, a genetic condition that leaves the lungs vulnerable to progressive damage. It belongs to a class of treatments called augmentation therapy, which works by replacing a protective protein the body can’t produce enough of on its own. Glassia is specifically approved for adults who have this deficiency along with signs of lung disease, particularly emphysema.
How Alpha-1 Antitrypsin Deficiency Damages the Lungs
Your body normally produces a protein called alpha-1 antitrypsin (AAT) in the liver, which then circulates through the bloodstream to the lungs. Its primary job is to neutralize an enzyme called neutrophil elastase, a substance released by white blood cells during their normal immune activity. Neutrophil elastase breaks down damaged or infected tissue, but without enough AAT to keep it in check, it also breaks down healthy lung tissue over time.
People with alpha-1 antitrypsin deficiency inherit faulty genes that result in low circulating levels of the protein. With less AAT reaching the lungs, the inflammatory damage accumulates, gradually destroying the air sacs and leading to emphysema. This process often begins earlier in life than typical smoking-related emphysema, sometimes appearing in a person’s 30s or 40s. Beyond its role against elastase, AAT also helps clear mucus from the airways, reduces cell death, and has anti-inflammatory and antioxidant effects, so its absence creates problems on multiple fronts.
Who Qualifies for Treatment
Not everyone with alpha-1 antitrypsin deficiency needs Glassia. Current clinical guidelines recommend augmentation therapy for non-smoking or former-smoking adults with COPD whose lung function has already declined (below 80% of predicted capacity on breathing tests) and who have confirmed deficiency genotypes with severely reduced AAT blood levels, specifically below 11 micromoles per liter. Treatment is intended to be used alongside standard COPD therapies like bronchodilators and pulmonary rehabilitation, not as a replacement for them.
Glassia is contraindicated in people who have IgA deficiency with antibodies against IgA. Because the product may contain trace amounts of IgA, these patients face a higher risk of severe allergic reactions, including anaphylaxis.
What Glassia Does in the Body
Glassia delivers a concentrated form of human alpha-1 antitrypsin protein directly into the bloodstream through an intravenous infusion. Once circulating, the protein travels to the lungs and binds to neutrophil elastase, preventing it from chewing through healthy tissue. The goal isn’t to reverse existing damage but to slow the rate at which the lungs continue to deteriorate.
Infusions are given once per week. Glassia was notable as the first liquid, ready-to-use formulation of AAT therapy approved by the FDA, meaning it doesn’t require the reconstitution step that older freeze-dried versions do. This made home infusion more practical for many patients after they receive proper training.
Evidence That It Slows Lung Damage
The strongest evidence for AAT augmentation therapy comes from the RAPID clinical trial program, which measured lung tissue density on CT scans as a way to track emphysema progression. Over the first two years, patients receiving AAT therapy lost lung density at a rate of 1.51 grams per liter per year, compared to 2.26 grams per liter per year in those on placebo. That’s roughly a 33% reduction in the speed of tissue loss.
The follow-up study, RAPID-OLE, was equally telling. Patients who had been on placebo for two years and then switched to active treatment saw their rate of decline slow immediately after the switch, preserving an average of 0.52 grams per liter per year compared to their time on placebo. Meanwhile, patients who had been on treatment from the start maintained their slower rate of decline over the full four-year observation period. This pattern, where starting earlier preserved more lung tissue and the benefit held steady over time, provided strong evidence that the treatment effect was real and sustained.
How the Product Is Made Safe
Glassia is derived from pooled human blood plasma, which naturally raises questions about infectious disease risk. The manufacturing process addresses this through multiple layers of safety. Donors are screened and tested for blood-borne viruses. The plasma pools themselves are tested for viral markers before processing begins. During manufacturing, the product undergoes dedicated pathogen inactivation steps designed to neutralize both common viruses like HIV and hepatitis and harder-to-kill nonenveloped viruses. These steps can include heat treatment and chemical processes that disrupt viral membranes without damaging the therapeutic protein. Additional purification through filtration and chromatography physically removes viral particles as well.
What to Expect During Treatment
Glassia is a weekly commitment. Each infusion delivers the replacement protein intravenously, and the treatment is ongoing because the body continuously needs fresh AAT to protect the lungs. There is no defined endpoint; stopping treatment means AAT levels drop back down and the accelerated lung damage resumes.
Some patients receive their infusions at an infusion center, while others transition to home infusion after being trained on proper technique. Common side effects reported in clinical trials include headache, dizziness, and infusion-site reactions. Serious allergic reactions are rare but possible, particularly in the IgA-deficient population mentioned above. Because the treatment slows progression rather than reversing it, patients generally won’t feel a dramatic improvement in breathing. The benefit shows up over years as preserved lung function compared to what would have been lost without treatment.